Signadori Bio appoints Dr Selwyn Ho as CEO to drive company growth
Signadori Bio, a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours, recently announced the appointment of Dr. Selwyn Ho as Chief Executive Officer. Dr. Ho is an experienced biopharma and biotech executive, with nearly 30 years of experience across commercialisation, drug development and multiple […]
